Indianapolis, IN, United States of America

Alby David Sharknas


Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 108(Granted Patents)


Company Filing History:


Years Active: 2006

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Alby David Sharknas: Innovator in Pharmaceutical Compositions

Introduction

Alby David Sharknas is a notable inventor based in Indianapolis, IN (US). He has made significant contributions to the field of pharmaceutical compositions, particularly in enhancing the stability of polypeptide formulations.

Latest Patents

Sharknas holds a patent for "Polypeptide compositions with improved stability." This invention provides methods to improve the chemical stability of aqueous, parenteral pharmaceutical compositions that include a polypeptide and glycerin. The patent identifies reactive aldehydes present in commercial glycerins and offers solutions for reducing their impact. It also presents convenient methods for assaying reactive aldehydes in glycerin, demonstrating a strong linear correlation between the levels of these aldehydes and the chemical stability of the compositions. The invention results in aqueous compositions that exhibit improved chemical stability compared to previously known formulations.

Career Highlights

Alby David Sharknas is associated with Eli Lilly and Company, a leading pharmaceutical firm. His work focuses on developing innovative solutions that enhance the efficacy and safety of pharmaceutical products.

Collaborations

Sharknas has collaborated with notable colleagues, including Michael Rosario DeFelippis and Michael Allen Dobbins, contributing to advancements in their shared field of expertise.

Conclusion

Alby David Sharknas is a distinguished inventor whose work in polypeptide compositions has the potential to significantly impact the pharmaceutical industry. His innovative approaches to improving chemical stability are paving the way for safer and more effective medical treatments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…